Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 + Nab-paclitaxel + Tislelizumab in Previously-treated Solid Tumors
NCT05982522Phase 2Withdrawn
- Sponsor
- InxMed
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ifebemtinib in solid tumor, non-small cell lung cancer (NSCLC), sponsored by InxMed. Planned start Aug 2025; status: withdrawn.
02
Drugs
ifebemtinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05982522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982522.